

GCCA Blog

Date

13 May 25

Categories

[Policy](#) [News](#) [Advocacy](#)

Share

GCCA on "Most Favored Nation" Drug Pricing Executive Order

Read GCCA's statement on Trump's "most favored nation" drug pricing policy.



Written by GCCA | 1 min read

Andrew Spiegel, CEO of the Global Colon Cancer Association (GCCA), released the following statement in response to the White House's executive order instituting a "most favored nation"(MFN) pricing policy for prescription drugs:

"The Global Colon Cancer Association strongly opposes the Trump administration's decision to move forward with the MFN policy. While we share the goal of lowering costs for American patients, this policy is not the solution -- it's a dangerous misstep that would put patients at risk.

The MFN model effectively imports foreign price controls into the American healthcare system by mandating that U.S. drug prices match the lowest prices paid in other countries. These countries' health systems routinely undervalue medicines, restrict access to cutting-edge therapies, and diminish the

incentives needed to develop the next generation of treatments for cancer and other life-threatening diseases.



GCCA on "Most Favored Nation" Drug Pricing Executive Order

[Read article](#)

the world in medical innovation, delivering improved patient outcomes. Undermining that mandates could siphon funding away from critical

research and weaken the very ecosystem that makes medical advances possible in the first place.

For patients with complex diseases like colon cancer, the stakes are especially high. Nearly 2 million people are diagnosed with colon cancer each year, and more than 900,000 die from it. These patients depend on timely access to advanced treatments. Blunt price-setting policies that ignore the real costs and risks of innovation could not only undermine long-term progress -- but also cause immediate harm by triggering drug shortages, treatment delays, and reduced access to care for those who need it most.

GCCA urges the White House to reconsider this policy. The administration should work with stakeholders across the healthcare system to develop alternative solutions that address affordability challenges while preserving the innovation ecosystem patients rely on. True reform should expand access to medical breakthroughs -- not restrict it.

We remain committed to advancing reforms that put patients first and protect continued access to life-saving innovation."

For further information, please contact info@globalcca.org.

Related articles

BLOG

Global Early Onset Colorectal Cancer Think Tank

Learn more about the think tank
June 18-19 in Barcelona, Spain.

BLOG

Mexico 2025: Patient Advocacy Mentorship with FUTEJE

Learn more about GCCA's
partnership with FUTEJE.

BLOG

GCCA on "Most Favored Nation" Drug Pricing Executive Order

Read GCCA's statement on Trump's
"most favored nation" drug pricing
policy.



Global Colon Cancer Association is a 501(c)3 not-for-profit organization with Tax ID No: 46-0657002

INFORMATION ON THIS WEB SITE IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND IS NOT A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE

About us

- About
- Become a member
- Find a member
- Program overview
- Contact us

Our programs

- Know Your Biomarker
- Transforming Policy
- Global CRC Congress
- CRC Health Equity Grants
- Blue Hat Bow Tie for CRC Awareness
- Patient Advocacy Mentorship
- Clinical Trial Awareness
- Colon Cancer Connected
- Biosimilars Training Program

Join the movement

Get the latest news & updates

Email *

☐ I agree to receive other communications from Global Colon Cancer Association.

Sign up

